New immune therapy aims to stop relapse in kids with aggressive T-Cell cancer
NCT ID NCT07476027
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a single infusion of CD7 CAR-T cells in 10 children with high-risk T-cell acute lymphoblastic leukemia or lymphoma who have already achieved remission. The goal is to see if this immune cell therapy can safely eliminate remaining cancer cells and reduce the chance of relapse. Researchers will monitor side effects and treatment response closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD7 CAR-T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could help prevent relapse in children with high-risk T-cell leukemia/lymphoma after initial treatment.
- What could go wrong
- This is a very early, small trial (10 people) with no results yet. The therapy may cause severe side effects or fail to prevent relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat T-Cell cancers
- Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
- New combo aims to wipe out hidden leukemia cells
- Double-Team attack: new CAR-T therapy targets two cancer markers to outsmart relapse
- Blood cancer transplant trial using banked donor marrow pulled before start
- New combo therapy aims to crush T-Cell blood cancers